Drug intelligence / Profile preview

atovaquone + azithromycin

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

Atovaquone + azithromycin is a combination therapy primarily used for the treatment of babesiosis, a tick-borne parasitic infection. This regimen has been shown to be as effective as the alternative combination of clindamycin and quinine but is associated with significantly fewer adverse reactions. The combination works by targeting the Babesia parasites through different mechanisms, with atovaquone interfering with electron transport in parasite mitochondria and azithromycin inhibiting protein synthesis by binding to the 50S ribosomal subunit.

Other names: atovaquone and azithromycinatovaquone/azithromycin

Targets

bc1 complex (Cytochrome bc1 complex (plasmodium))60S (Eukaryotic 60S ribosomal subunit)

Beyond the preview

Go deeper on atovaquone + azithromycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on atovaquone + azithromycin.

Explore the full profile